Elise Harcourt
Elise Harcourt writes for Floto Review and other Independent Journal publications, covering IPOs, direct listings and exchange listings and SEC filings and securities regulation. Reporting under this byline is prepared by the Independent Journal editorial desk from primary sources, with AI assistance, and reviewed under our editorial policy.
8 articles
Retension Pharmaceuticals Files 424B4 Prospectus for IPO
Retension Pharmaceuticals filed its final 424B4 prospectus with the SEC on Oct. 9, 2026. Here is what the filing signals and what to check in the pricing terms.
Cyient's AI Engineering Unit: A Signal for Tech Companies
Cyient has set up an Intelligent Engineering Solutions unit and launched CYiNGINE, a platform-led AI model for lifecycle engineering. Here is what is known so far.
Hovione's Tableting News vs. a SPAC 424B4 Prospectus
Hovione's continuous tableting announcement landed in an IPO news feed, but it isn't a listing event. A SPAC's 424B4 prospectus filing is what to watch.
Electra Therapeutics IPO Pricing: $350 Million at $15 a Share
Electra Therapeutics priced 23.3 million shares at $15 in its September 2026 Nasdaq IPO. Our review of the 424B4 prospectus, pipeline, losses and cash.
How IPO pricing works: from price range to final prospectus
How IPO pricing works: underwriters, the order book, the price range and the final 424B4 prospectus, explained in plain English for general readers today.
OceanLight Acquisition IPO Pricing: $100 Million on Nasdaq
OceanLight Acquisition Corp priced a $100 million SPAC IPO at $10 a unit on Nasdaq, with rights and warrants in each unit and a closing 8-K detailing the sale.
Jersey Mike's IPO Pricing: $23 a Share and a $1 Billion Offering
Jersey Mike's Subs priced 43.5 million shares at $23 in its July 2026 NYSE IPO, a $1 billion deal. Our 424B4 review covers proceeds, debt and control.
Lincoln International IPO Pricing: $20 a Share in NYSE Debut
Lincoln International priced 21 million Class A shares at $20 in its May 2026 NYSE IPO. Our 424B4 review covers proceeds, debt paydown and partner control.